

Inhibition of Corneal Neovascularization with Propolis Extract

Maryam Keshavarz, Ali Mostafaie, Kamran Mansouri, Yadollah Shakiba, and
Hamid Reza Mohammadi Motlagh

Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Introduction

Corneal neovascularization is a complication of many entities including infectious keratitis, corneal trauma, alkali injury, and contact lens wear (1). Corneal neovascularization can present a serious problem for some patients who may experience glare, photophobia, or visual loss secondary to corneal scarring and lipid deposition (2). Corneal avascularity requires low levels of angiogenic factors and high levels of anti-angiogenic factors under basal conditions. Rupture of this homeostasis may occur in the pathogenesis of corneal neovascularization (3). Several anti-angiogenic agents have been characterized to inhibit corneal neovascularization in recent years in animal models. Fumagillin analogs (4), thalidomide (5), cyclosporine A (6), and oral shark cartilage (7) all exhibit anti-angiogenic activity in cornea. Tight regulation of corneal neovascularization helps maintain the transparency and immune privilege of the cornea (8).

Mechanism of Neovascularization

Angiogenesis, the formation of new blood capillaries from pre-existing capillaries, can be separated into several main steps including digestion of basement membrane and extracellular matrix (ECM), migration, proliferation, and rearrangement of endothelial cells to form new blood vessels (9). Currently anti-angiogenic strategies are based on inhibition of endothelial cell adhesion and migration and interference with metalloproteinase (10–12). Matrix metalloproteinases (MMPs) and angiogenic growth factors are the main factors that modulate neovascularization. MMPs can degrade the basal membranes and ECM surrounding the sprouting capillaries. On the other hand, angiogenic growth factors, vascular endothelial growth factor (VEGF) and fibroblast growth factor stimulate proliferation and migration of vascular endothelial cells (13). Many investigations have supported a causal role for VEGF in corneal neovascularization (14–20). VEGF overexpression in cornea stimulates proteolytic activities, proliferation, migration, and tube formation of endothelial cells and initiates formation of new blood vessels (3). Interestingly, requirement of VEGF in corneal angiogenesis was shown by the inhibition of neovascularization after stromal

Address reprint requests to: Ali Mostafaie, PhD, Medical Biology Research Center, P.O. Box 1568, Sorkheh Lige, Kermanshah, Iran; E-mail: amostafaie@kums.ac.ir

implantation of an anti-VEGF blocking antibody in a rat model (21,22). At least two VEGF inhibitors are in advanced clinical development for ophthalmic disease, Lucentis (rhuFab V2; Genentech, Inc., San Francisco, CA) and Macugen (pegaptanib sodium; Eyetech Pharmaceuticals, New York, NY) and more are poised to enter to clinical practice (23).

MMPs are a tightly regulated family of zinc-dependent endopeptidases capable of degrading all components of the ECM and basement membrane (24). Several MMPs are believed to be important in angiogenesis, but particular interest has been focused on the MMP-2 and MMP-9 (25). Several studies have shown that MMP-2 expression is upregulated in corneal neovascularization (26–29). Two recent studies investigated corneal neovascularization in MMP-2-deficient mice compared with wild-type mice and showed statistically significant delay of neovascularization in MMP-2 deficient mice (30,31). Another study reported that MMP-2 is required for optimal experimental choroidal neovascularization in a mouse model (32).

Propolis Extract and Angiogenesis

Together these data indicate that proliferation, migration and capillary tube formation are necessary steps for corneal neovascularization. Consequently, any mechanism that interferes with angiogenesis steps or angiogenesis factors like VEGF or MMPs may limit the visual loss associated with corneal neovascularization. Therefore, we propose the hypothesis that local administration of propolis extract may be effective in corneal neovascularization treatment. Propolis, a sticky material that honeybees collect from living plants, has been reported to have multiple biological effects (33–39). The postulated role of propolis extract in treatment of corneal neovascularization rests on its ability for suppressing angiogenesis. Several studies obviously showed that propolis extract and its fractions, especially artemillin C and caffeic acid phenyl ester, are effective in cancer treatment because of their ability to induce apoptosis and reduce secretion of major stimulatory factors involved in cell proliferation and angiogenesis (37–47). Hepşen et al. (39) reported that topical application of a water extract of propolis has an inhibitory effect on corneal neovascularization in rabbit's cornea injured by silver nitrate cauterization. They suggested that the inhibitory effect of propolis is partially due to the activity of both cyclo- and lipo-oxygenase. Another recent study on human umbilical vein endothelial cells showed that propolis extract can 1) inhibit proliferation of endothelial cells, 2) reduce endothelial cell migration and 3) inhibit HUVEC capillary tube formation in a dose-dependent manner (43). Moreover, it has been reported that oral administration of propolis extract suppressed tumor-induced angiogenesis *in vivo* (43). Furthermore artemillin C component alone can suppress angiogenesis in *in vivo* and *in vitro* models, and caffeic acid

phenyl ester can inhibit MMP-2, MMP-9 and VEGF activity (38,40,42,43). These data strongly suggest that propolis extract and its components can treat corneal neovascularization by inhibiting critical steps in angiogenesis such as proliferation, migration, tube formation and inhibition of involving factors like VEGF and MMP2, MMP-9 secretion. To test this hypothesis, we propose local use of propolis extract as ophthalmic drops in corneal neovascular states such as alkali burn, infections, stem cell deficiency, stromal keratitis, and corneal graft rejection. Before clinical application, the propolis extract and its responsible components should be tested in appropriate animal models of corneal neovascularization.

References

1. Lee P, Wang CC, Adamis AP. Ocular neovascularization. An epidemiologic review. *Surv Ophthalmol* 1998;433:245–269.
2. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection their manifestations, frequency, preoperative correlates, and treatment. *Arch Ophthalmol* 1981;994:599–604.
3. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. *Curr Opin Ophthalmol* 2001;124:242–249.
4. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. *Nature* 1990;348:555–557.
5. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. *Exp Eye Res* 1997;646:971–978.
6. Benelli U, Ross JR, Nardi M, Klintonworth GK. Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A. *Invest Ophthalmol Vis Sci* 1997;382:274–282.
7. Gonzales RP, D-Soares FS, Farias RF, Pessoa C, Leyva A, de Barros Viana GC, et al. Demonstration of inhibitory effect of oral shark cartilage on basic fibroblast growth factor-induced angiogenesis in the rabbit cornea. *Biol Pharm Bull* 2001;24:151–154.
8. Huang AJ, Watson BD, Hernandez E, Tseng SC. Induction of conjunctival transdifferentiation on vascularized corneas by photothrombotic occlusion of corneal neovascularization. *Ophthalmology* 1998;952:228–235.
9. Plank MJ, Sleeman BD. Tumor-induced angiogenesis: a review. *J Theor Med* 2004;5:137–153.
10. Murray JC. *Methods in Molecular Medicine: Angiogenesis Protocols*. Totowa, NJ: Humana Press;2001. pp. 185–203 and 463–520.
11. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev* 2004;25:581–611.
12. Haider AS, Grabarek J, Eng B, Pedraza P, Ferreri NR, Balazs EA, et al. *In vitro* model of wound healing analyzed by laser scanning cytometry: accelerated healing of epithelial cell monolayer in the presence of hyaluronate. *Cytometry Part A* 2003;53A:1–8.
13. D'Amore PA, Thompson RW. Mechanism of angiogenesis. *Annu Rev Physiol* 1987;49:453–464.
14. Singh N, Amin S, Richter E, Rashid S, Scoglietti V, Jani PD, et al. Flt-1 intraceptors inhibits hypoxia-induced VEGF expression *in vitro* and corneal neovascularization *in vivo*. *Invest Ophthalmol Vis Sci* 2005;465:1647–1652.
15. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor VEGF and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. *Acta Ophthalmol Scand* 2004;825:557–563.
16. Jousseaume AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, et al. VEGF-dependent conjunctivalization of the corneal surface. *Invest Ophthalmol Vis Sci* 2003;441:117–123.

17. Zhou LH, Xing YQ, Chen CL, Wang DW. Antisense vascular endothelial growth factor suppressed corneal neovascularization in rats. *Zhonghua Yan Ke Za Zhi* 2006;425:426–430.
18. Murata M, Takanami T, Shimizu S, Kubota Y, Horiuchi S, Habano W, et al. Inhibition of ocular angiogenesis by diced small interfering RNAs siRNAs specific to vascular endothelial growth factor VEGF. *Curr Eye Res* 2006;312:171–180.
19. Lai CM, Spilsbury K, Brankov M, Zaknich T, Rakoczy PE. Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. *Exp Eye Res* 2002;756:625–634.
20. Chen J, Liu W, Liu Z, Chen L, Huang T, Zhen H. Expression of vascular endothelial growth factor and its receptors flt-1 in morbid human corneas and investigation of its clinic importance. *Yan Ke Xue Bao* 2002;184:203–207.
21. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. *Invest Ophthalmol Vis Sci* 1998;391:18–22.
22. Paul Aiello L, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al. Suppression of retinal neovascularization *in vivo* by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. *Proc Natl Acad Sci U S A* 1995;92:10457–10461.
23. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. *Retina* 2005;252:111–118.
24. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. *Trends Genet* 1990;6:121–125.
25. Sethi CS, Bailey TA, Luthert PJ, Chong NHV. Matrix metalloproteinase biology applied to vitreoretinal disorders. *Br J Ophthalmol* 2000;84:654–666.
26. Kato T, Kure T, Chang JH, Gabison EE, Itoh T, Itohara S, et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. *FEBS Lett* 2001;5082:187–190.
27. Zhang H, Li C, Baci PC. Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis. *Invest Ophthalmol Vis Sci* 2002;434:955–962.
28. Rigal-Sastourne JC, Tixier JM, Renard JP, Maurin JF, Pouliquen Y, Legeais JM. Corneal burns and matrix metalloproteinases MMP-2 and -9: the effects of human amniotic membrane transplantation. *J Fr Ophtalmol* 2002;257:685–693.
29. Ma DH, Chen JK, Kim WS, Hao YX, Wu HC, Tsai RJ, et al. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization. *Ophthalmic Res* 2001;336:353–362.
30. Samolov B, Steen B, Seregard S, van der Ploeg I, Montan P, Kvanta A. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. *Exp Eye Res* 2005;802:159–166.
31. Ohno-Matsui K, Uetama T, Yoshida T, Hayano M, Itoh T, Morita I, et al. Reduced retinal angiogenesis in MMP-2-deficient mice. *Invest Ophthalmol Vis Sci* 2003;44:5370–5375.
32. Berglin L, Sarman S, van der Ploeg I, Steen B, Ming Y, Itohara S, et al. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. *Invest Ophthalmol Vis Sci* 2003;441:403–408.
33. De Castro SL. Propolis: biological and pharmacological activities. Therapeutic uses of this bee-product. *Annu Rev Biomed Sci* 2001;3:49–83.
34. Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. *Apidologie* 1995;26:83–99.
35. Nakajima Y, Shimazawa M, Mishima S, Hara H. Water extract of propolis and its main constituents, caffeoylquinic acid derivatives, exert neuroprotective effects via antioxidant actions. *Life Sci* 2007;80:370–377.
36. Burdock GA. Review of the biological properties and toxicity of bee propolis (Propolis). *Food Chem Toxicol* 1988;36:347–363.
37. Frenkel K, Wei H, Bhimani R, Ye J, Zadunaisky JA, Huang MT, et al. Inhibition of tumor promoter-mediated processes in mouse skin and bovine lens by caffeic acid phenethyl ester. *Cancer Res* 1993;53:1255–1261.
38. Hwang HJ, Park HJ, Chung, Min HJ, Park EJ, Hong JY, et al. Inhibitory effects of caffeic acid phenethyl ester on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells. *J Nutr Biochem* 2006;17:356–362.
39. Hepşen IF, Er H, Cekiç O. Topically applied water extract of propolis to suppress corneal neovascularization in rabbits. *Ophthalmic Res* 1999;31:426–431.
40. Jin UH, Chunga TW, Kanga SK, Suh SJ, Kim JK, Chung KH, et al. Caffeic acid phenyl ester in propolis is a strong inhibitor of matrix metalloproteinase-9 and invasion inhibitor: isolation and identification. *Clin Chim Acta* 2005;362:57–64.
41. Kuo HC, Kuob WH, Lee YJ, Lind WL, Choua FP, Tsenge TH. Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells *in vitro* and *in vivo*. *Cancer Lett* 2006;234:199–208.
42. Liao HF, Chen YY, Liu JJ, Hsu ML, Shieh HJ, Liao HJ, et al. Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, and metastasis. *J Agr Food Chem* 2003;51:7907–7912.
43. Ahn MR, Kunimasa K, Ohta T, Kumazawa S, Kamihira M, Kaji K, et al. suppression of tumor-induced angiogenesis by Brazilian propolis: major component artepillin C inhibits *in vitro* tube formation and endothelial cell proliferation. *Cancer Lett* 2007;252:235–243.
44. Scheller S, Krol W, Swiacik J, Owczarek S, Gabrys J, Shani J. Antitumoral property of ethanolic extract of propolis in mice-bearing Ehrlich carcinoma, as compared to bleomycin. *Z Naturforsch* 1989;44c:1063–1065.
45. Matsuno T, Chen C, Basnet P. A tumoricidal and antioxidant compound isolated from an aqueous extract of propolis. *Med Sci Res* 1997;25:583–584.
46. Kimoto T, Arai Kohguchi M, Aga M, Nomura Y, Micallef MJ, Kurimoto M, et al. Apoptosis and suppression of tumor growth by artepillin C extracted from Brazilian propolis. *Cancer Detect Prev* 1998;22:506–515.
47. Shimizua K, Dasa SK, Babab M, Matsuurac Y, Kanazawaa K. Dietary artepillin C suppresses the formation of aberrant crypt foci induced by azoxymethane in mouse colon. *Cancer Lett* 2006;240:135–142.